Advances in Antiviral Drug Design

- Volume 3

af

indgår i serie Advances in Antiviral Drug Design


Advances in Antiviral Drug Design
Du sparer Spar kr. 50,00 med Saxo Premium
Format:
Bog, hardback
Udgivelsesdato:
01-10-1999
Sprog:
Engelsk
  • Beskrivelse
  • Yderligere info
  • Anmeldelser

Volume 3 of Advances in Antiviral Drug Design is keeping up with the recent progress made in the field of antiviral drug research and highlights five specific directions that have opened new avenues for the treatment of virus infections. First, the use of lamivudine (3TC) for the treatment of HIV infections, and its more recent introduction for the treatment of hepatitis B virus (HBV) infections, has heralded the transition of D- to L-nucleosides in the antiviral nucleoside drug design, and it is likely that the future will provide more nucleosides of the L-configuration, such as (-)FFC (emtricitabine) and L-FMAU, as will be described by J.-C.G. Graciet and R.F. Shinazi. Second, the acyclic purine nucleoside phosphonates, i.e. PMEA (adefovir and PMPA (tenofovir), offer great potential as both anti-HIV and anti-HBV agents, and both compounds have been the subject of advanced clinical trials in their oral produrg form (adefovir dipivoxil and tenofovir disoproxyl), as mentioned by M.N. Arimilli, J.P. Dougherty, K.C. Cundy, and N. Bischofberger.Third, with the advent of nevirapine, delavirdine, and efavirenz, the NNRTIs have definitely come of age. Emivirine (MKC-442), a derivative of the original HEPT analog that was described in 1989 has now proceeded through pivotal clinical studies, and how this class of compounds evolved is presented in the account of H. Tanaka and his colleagues. Fourth, at the end of 1999, anticipating on the next winter influenza offensive, we should have at end two compounds that specifically inhibit influenza A and B virus infections: zanamivir (by the intranasal route) and oseltamivir (by the oral route). Both compounds have proved effective in the prophylaxis and treatment of influenza A and B virus infections and act through the same mechanism; that is by blocking the viral neuraminidase (or sialidase), a key enzyme that allows the virus to spread from one cell to another (within the respiratory mucosal tract). The design of these sialidase inhibitors will be presented by M. von Itzstein and J.C. Dyason.Fifth, the discovery (in 1996) of the chemokine receptors CXCR4 and CCR5 as essential coreceptors (in addition to the CD4 receptor) for HIV entry into the cells, has boosted an enormous interest in potential antagonists of these receptors. The bicyclams represent the first low-molecular-weight compounds targeted at CXCR4, the coreceptor used by the more pathogenic, T-lymphotropic, HIV strains, to enter the cells. They will be addressed by G.J. Bridger and R.T. Skerlj.The five topics covered in this third volume of Advances in Antiviral Drug Design are in the front line of the present endeavors towards the chemotherapy of virus infections. They pertain to the combat against three of the most important virus infections of current times: HIV, HBV, and influenza virus.

Vis mereVis mindre

Udgivelsesdato:
01-10-1999
ISBN13:
9780762302017
Vægt:
550 g
Dybde:
25 mm
Bredde:
150 mm
Højde:
230 mm
Nummer i serien:
v. 3
Nummer i serien:
v. 3
Format:
Hardback
  • Forfattere

  • Bibliotekernes beskrivelse

    Covers the progress made in the field of antiviral drug research and highlights five specific directions that have opened fresh avenues for the treatment of virus infections including HIV, HBV and influenza virus.

Vis mereVis mindre

Vis mereVis mindre

Advances in Antiviral Drug Design

- Volume 3

af

indgår i serie Advances in Antiviral Drug Design

  • Leveringstid 2-3 uger
  • Forventet levering 11-10-2019
Køb til medlemspris og få altid fri fragt.
Prøv 30 dage gratis (herefter 99,-/md.).

Læs mere om Saxo Premium her.

på lager

Fandt du ikke hvad du søgte?

Hvis denne bog ikke er noget for dig, kan du benytte kategorierne nedenfor til at finde andre titler. Klik på en kategori for at se lignende bøger.

Velkommen til Saxo

Du har nu adgang til din konto hos Saxo, og kan se alle oplysninger om dit medlemskab, dine
ordrer og din digitale boghylde under "Mit Saxo".

Som tak for, at du har aktiveret dit medlemskab, har vi valgt at give dig fri læsning hele
sommeren. Dvs. at du frit kan tilgå de mere en 50.000 bøger i Saxos app, samt købe bøger til
vores altid lave medlemspris og fri fragt her på Saxo.com hele juli. Din næste medlemsbetaling
vil først falde i august.

Vi glæder os meget til at byde dig velkommen i vores univers, og håber at du kommer godt i
gang med Saxo Premium.

God sommer og god læselyst!

Med venlig hilsen Saxo

Kom i gang nu!